Artivion outlines double-digit revenue growth target for 2025 as AMDS and On-X momentum builds [Seeking Alpha]
Artivion, Inc. (AORT)
Company Research
Source: Seeking Alpha
CEO Pat MacKin highlighted "total constant currency revenue growth of 16% and adjusted EBITDA growth of 39% year-over-year" and pointed to continued momentum across the portfolio, especially in stent grafts and On-X valves. Stent graft revenues grew Quick Insights Growth is driven by strong stent graft (AMDS) and On-X valve performance, favorable clinical data, and operational execution, resulting in 16% revenue and 39% EBITDA growth year-over-year. Management expects continued momentum for both products due to increased adoption, new reimbursement support (AMDS), and further market share gains (On-X), though tougher AMDS comparables and higher R&D costs pose risks. Artivion raised its 2025 revenue and adjusted EBITDA outlook, projecting double-digit top-line growth and EBITDA outpacing revenue, with modest margin expansion expected and similar dynamics anticipated for 2026 apart from specific expense pressures. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest [Yahoo! Finance]Yahoo! Finance
- Strong Q3 Results and Raised Outlook Could Be a Game Changer for Artivion (AORT) [Yahoo! Finance]Yahoo! Finance
- 2 Unpopular Stocks That Deserve a Second Chance and 1 Facing Challenges [Yahoo! Finance]Yahoo! Finance
- Artivion (AORT): Is the Healthcare Standout Fairly Valued After Recent Surge? [Yahoo! Finance]Yahoo! Finance
AORT
Earnings
- 11/6/25 - Beat
AORT
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/3/25 - Form 4
- AORT's page on the SEC website